Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods

Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods AbstractParkinson’s disease (PD) is a chronic neurodegenerative disorder that is clinically manifested by motor and non-motor symptoms. At the early stage of the disease, it can be misdiagnosed with some neurologic disorders due to overlapping or similar clinical features. In addition, the pathogenesis of this disease is initiated several years prior to the appearance of classical motor symptoms. This latent phase of neurodegeneration in PD characterised at cellular level by preservation of significant fraction of dopaminergic neurones is of particular interest with respect to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease with an aim to slow down or reverse the disease progression. Therefore, huge effort was performed in order to find and validate a biomarker that would reliably differentiate PD from other neurologic diseases as well as a biomarker that would reveal preclinical/prodromal stage of PD. This short review summarises a recent progress in validation of molecular biomarkers of PD, distinct from genetic markers of PD, with some focus on new analysed tissues and new methods. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Medica Martiniana de Gruyter

Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods

Peter, Racay
Acta Medica Martiniana , Volume 23 (1): 8 – Apr 1, 2023
Download PDF
8 pages

Loading next page...
 
/lp/de-gruyter/search-for-molecular-biomarkers-of-parkinson-s-disease-new-tissues-and-VBJAqbFztz

References (51)

Publisher
de Gruyter
Copyright
© 2023 Racay P., published by Sciendo
ISSN
1335-8421
eISSN
1338-4139
DOI
10.2478/acm-2023-0003
Publisher site
See Article on Publisher Site

Abstract

AbstractParkinson’s disease (PD) is a chronic neurodegenerative disorder that is clinically manifested by motor and non-motor symptoms. At the early stage of the disease, it can be misdiagnosed with some neurologic disorders due to overlapping or similar clinical features. In addition, the pathogenesis of this disease is initiated several years prior to the appearance of classical motor symptoms. This latent phase of neurodegeneration in PD characterised at cellular level by preservation of significant fraction of dopaminergic neurones is of particular interest with respect to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease with an aim to slow down or reverse the disease progression. Therefore, huge effort was performed in order to find and validate a biomarker that would reliably differentiate PD from other neurologic diseases as well as a biomarker that would reveal preclinical/prodromal stage of PD. This short review summarises a recent progress in validation of molecular biomarkers of PD, distinct from genetic markers of PD, with some focus on new analysed tissues and new methods.

Journal

Acta Medica Martiniana – de Gruyter

Published: Apr 1, 2023

Keywords: Parkinson’s disease; neurodegeneration; biomarker

There are no references for this article.